Hudson Bay Capital Management LP Athira Pharma, Inc. Transaction History

Hudson Bay Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.93 - $3.96 $47,173 - $63,756	-16,100 Reduced 3.39%	458,900 $1.36 Million
Q2 2022 Aug 12, 2022	BUY	$2.74 - $13.43 $383,600 - $1.88 Million	140,000 Added 41.79%	475,000 $1.45 Million
Q1 2022 May 16, 2022	BUY	$8.96 - $13.51 $1.21 Million - $1.82 Million	135,000 Added 67.5%	335,000 $4.52 Million
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $457,500 - $554,500	50,000 Added 33.33%	200,000 $1.88 Million
Q2 2021 Aug 16, 2021	BUY	$10.24 - $20.87 $1.54 Million - $3.13 Million	150,000 New	150,000 $1.54 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $23.4M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.